[1-(Methoxy-methyl-carbamoyl)-pentyl]-carbamic acid tert-butyl ester | 254438-02-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [1-(Methoxy-methyl-carbamoyl)-pentyl]-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[1-[methoxy(methyl)amino]-1-oxohexan-2-yl]carbamate
• CAS: 254438-02-3
• 化学式: C₁₃H₂₆N₂O₄
• 分子量: 274.36
• InChiKey: PNYOAOWVAVVYRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [1-(Methoxy-methyl-carbamoyl)-pentyl]-carbamic acid tert-butyl ester 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 [1-(Cyano-hydroxy-methyl)-pentyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Novel inhibitors of hepatitis C NS3–NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid

  摘要：

  Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of similar to 3000 amino acids that is processed with the help of a serine protease NS3A to produce structural and non-structural proteins required for viral replication. Inhibition of NS3 protease can potentially be used to develop drugs for treatment of HCV infections. Herein, we report the development of a series of novel NS3 serine protease inhibitors derived from 2-aza-bicyclo[2.2.1]-heptane carboxylic acid with potential therapeutic use for treatment of HCV infections. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.046
• 作为产物：
  描述：

  2-((tert-butoxycarbonyl)amino)hexanoic acid 、 二甲羟胺盐酸盐 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 [1-(Methoxy-methyl-carbamoyl)-pentyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Novel inhibitors of hepatitis C NS3–NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid

  摘要：

  Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of similar to 3000 amino acids that is processed with the help of a serine protease NS3A to produce structural and non-structural proteins required for viral replication. Inhibition of NS3 protease can potentially be used to develop drugs for treatment of HCV infections. Herein, we report the development of a series of novel NS3 serine protease inhibitors derived from 2-aza-bicyclo[2.2.1]-heptane carboxylic acid with potential therapeutic use for treatment of HCV infections. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.046

文献信息

• N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
  申请人：G.D. Searle & Co.

  公开号：EP0508393A1

  公开（公告）日：1992-10-14

  A class of N-arylheteroarylalkyl imidazol-2-one compounds is described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Compounds of particular interest are angiotensin II antagonists of the formula wherein A is selected from wherein m is one; wherein R¹ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, 2-ethylbutyl, n-pentyl, neopentyl, phenyl, methylphenyl, difluorophenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R⁰ is hydrido; wherein R² is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R³, R⁴, R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ is hydrido and R⁵ must be selected from COOH, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH, wherein each of R⁴² and R⁴³ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-aceptable salt thereof.

  描述了一类 N-芳基杂芳基烷基咪唑-2-酮化合物，用于治疗高血压和充血性心力衰竭等循环系统疾病。特别感兴趣的化合物是式中的血管紧张素 II 拮抗剂 其中 A 选自 其中 m 为 1； 其中R¹选自甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、4-甲基丁基、2-乙基丁基、正戊基、新戊基、苯基、甲基苯基、二氟苯基苄基、苯乙基、环己基、环己基甲基、环己基乙基、环己基甲酰基、1-氧代-2-环己基乙基、苯甲酰基、1-氧代-2-苯乙基、1-氧代丙基、1-氧代丁基、1-氧代戊基和 2-羟基丁基；其中 R⁰为氢基；其中 R² 选自甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、正戊基、异戊基、新戊基、苯基、苄基、苯乙基、环己基、环己基甲基、丙硫基、丁硫基和羟烷基；其中 R³、R⁴、R⁶、R⁷、R⁸、R⁹、R¹⁰ 和 R¹¹ 中的每一个都是氢基，而 R⁵ 必须选自 COOH、SH、PO₃H₂、SO₃H、CONHNH₂、CONHNHSO₂CF₃、OH、 其中 R⁴² 和 R⁴³ 各自独立地选自氯、氰基、硝基、三氟甲基、甲氧羰基和三氟甲基磺酰基；或其同系物或其可药用盐。
• Calpain modulators and therapeutic uses thereof
  申请人：Blade Therapeutics, Inc.

  公开号：US10934261B2

  公开（公告）日：2021-03-02

  Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

  本文公开了小分子钙蛋白酶调节剂组合物、药物组合物及其用途和制备方法。
• [EN] N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS
  申请人：G.D. SEARLE & CO.

  公开号：WO1992007834A1

  公开（公告）日：1992-05-14

  (EN) A class of N-substituted imidazol-2-one compounds is described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of formula (I), wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, chlorophenyl, thienylethyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio and hydroxyalkyl; wherein each of R3, R4, R5, R6, R7, R8, R10 and R11 is hydrido; wherein R9 is selected from COOH and (II) or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.(FR) L'invention décrit une catégorie de composés d'imidazol-2-one substituée par N, utilisés dans le traitement de troubles circulatoires. Des composés offrant un intérêt particulier sont des antagonistes de l'angiotensine II et sont représentés par la formule (I) dans laquelle m vaut un; R1 est choisi parmi méthyle, éthyle, n-prophyle, isopropyle, n-butyle, sec-butyle, isobutyle, tert-butyle, 4-méthylbutyle, n-pentyle, néopentyle, phényle, chlorophényle, thiényléthyle, benzyle, phénéthyle, cyclohexyle, cyclohexylméthyle, cyclohexyléthyle, cyclohexanoyle, 1-oxo-2-cyclohexyléthyle, benzoyle, 1-oxo-2-phénéthyle, 1-oxopropyle, 1-oxobutyle, 1-oxopentyle et 2-hydroxybutyle; R0 est choisi parmi hydrido, méthyle, fluoro, chloro, monofluorométhyle, difluorométhyle, trifluorométhyle, formyle, carboxyle et diméthoxyméthyle; R2 est choisi parmi méthyle, éthyle, n-propyle, isopropyle, n-butyle, sec-butyle, isobutyle, tert-butyle, n-pentyle, isopentyle, néopentyle, phényle, benzyle, phénéthyle, cyclohexyle, cyclohexyméthyle, propylthio, butylthio et hydroxyalkyle; R3, R4, R5, R6, R7, R8, R10 et R11 sont chacun hydrido, R9 est choisi parmi COOH et (II) ou un automère ou bien un sel pharmaceutiquement acceptable de ceux-ci. Ces composés sont particulièrement utiles dans la lutte contre l'hypertension et l'insuffisance cardiaque congestive ou dans le traitement de celles-ci.

  描述了一类N-取代的二噁一酮化合物，用于治疗循环系统疾病。特别是对_heap; selves of particular interest are the angiotensin II antagonists of formula (I) ....
• N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS
  申请人：G.D. SEARLE & CO.

  公开号：EP0555331A1

  公开（公告）日：1993-08-18
• N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS
  申请人：G.D. SEARLE & CO.

  公开号：EP0579766B1

  公开（公告）日：1999-06-02